UBS AM
VERV

UBS AM’s Verve Therapeutics VERV Stock Holding History

UBS AM’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-183,610
Closed -$2.06M – 2616
2025
Q2 		$2.06M Buy
183,610
+50,044
+37% +$285K ﹤0.01% 2124
2025
Q1 		$610K Buy
133,566
+13,748
+11% +$92.1K ﹤0.01% 2455
2024
Q4 		$676K Buy
119,818
+4,777
+4% +$26.9K ﹤0.01% 2492
2024
Q3 		$557K Buy
115,041
+6,595
+6% +$38.3K ﹤0.01% 2611
2024
Q2 		$529K Buy
108,446
+61,854
+133% +$389K ﹤0.01% 2613
2024
Q1 		$619K Hold
46,592
– – ﹤0.01% 2221
2023
Q4 		$649K Hold
46,592
– – ﹤0.01% 2228
2023
Q3 		$618K Buy
46,592
+24,077
+107% +$388K ﹤0.01% 2200
2023
Q2 		$325K Hold
22,515
– – ﹤0.01% 2452
2023
Q1 		$325K Buy
22,515
+1,160
+5% +$22.7K ﹤0.01% 2452
2022
Q4 		$413K Sell
21,355
-6,147
-22% -$163K ﹤0.01% 2247
2022
Q3 		$945K Buy
27,502
+12,502
+83% +$399K ﹤0.01% 1999
2022
Q2 		$229K Buy
+15,000
New +$232K ﹤0.01% 2550
2022
Q1 		– Sell
-8,100
Closed -$299K – 2823
2021
Q4 		$299K Buy
+8,100
New +$340K ﹤0.01% 2677

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS AM's VERV Position: Q3 2025 in Review

UBS AM sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 183,610 shares — an estimated $2.06M sold.

UBS AM first reported a position in VERV in Q4 2021 and held it in 14 quarters. The position peaked at $2.06M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • UBS AM reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS AM sold 183,610 Verve Therapeutics shares in Q3 2025, an estimated $2.06M.
  • UBS AM first reported a position in Verve Therapeutics in Q4 2021 and held it in 14 quarters.
  • UBS AM's Verve Therapeutics position peaked at $2.06M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on UBS AM's 13F filing for Q3 2025, filed 14 Nov 2025.